Science: blocking vista is expected to improve the efficacy of cancer immunotherapy

January 18, 2020 / Biovalley BIOON / - -- in a new study, researchers from the University of Minnesota and the University of Dartmouth gaizel Medical College in the United States have studied an important target of regulating immune response in cancer and autoimmune diseases: Vista (V-domain Ig suppressor of T-cell activation, T-cell activation V-domain Ig inhibitor) As a regulatory molecule, Vista can prevent T cells in the immune system from being activated by autoantigens, such as those in cancer cells This new study describes how Vista controls T cell responses The relevant research results were published in the Science Journal on January 17, 2020 The title of the paper is "vista is a checkpoint regulator for Na य़ ve T cell quiescence and peripheral tolerance" The corresponding authors of the paper are Randolph Noelle, Ph.D., and Chao Cheng, Ph.D., of the gaizel School of medicine, Dartmouth Picture from science, 2020, DOI: 10.1126/science.aay0524 Although strong immune responses are needed to help protect the host from infection, the immune system must also suppress the intensity of these responses to limit the damage it may cause In the past eight to 10 years, Dr Noelle and his team have identified some molecules that the immune system uses to regulate the immune response Although these molecules usually play a beneficial role, they also limit the intensity of anti-tumor immune response Noelle's team learned that turning off the molecular "brakes" that inhibit immune responses can treat cancer Vista is one of these molecular brakes that negatively regulate the immune response "We already know that keeping the immune system at rest is a challenging process," Noelle said Vista mediates the function of the immune system, and its absence can lead to harmful immune response But Vista may also be an important target for regulating immune response in cancer and autoimmune diseases " Vista can keep the T cell compartment of the immune system still and prevent the immune system from activating autoantigens, such as those in cancer cells "Blocking vista in cancer, like other negative immune checkpoint regulators, may enhance the host's ability to produce tumor specific protective immune responses," Noelle said Currently, there is an antibody against vista that will be used in phase I clinical trials of cancer to see whether it is safe and whether it can enhance the immune response of patients to cancer If so, the antibody may have value in the development of drugs and vaccines for cancer treatment (bio Com) reference: 1 Mohamed a eltanbouly et al Vista is a checkpoint regulator for Na ï ve T cell quiescence and persistent tolerance Science, 2020, DOI: 10.1126/science.aay0524 2 Chrysothermis Brown et al Enforcing T cell innovation Science, 2020, DOI: 10.1126/science.aay0524 2 Researchers invest Mobile, VISTA, which keeps immune system quiet against cancerhttps://medicalxpress.com/news/2020-01-molecule-vista-immune-quiet-cancer.html